All In Biotech

Drug Trial Radar · NCT07413133

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

A Phase 1 Pharmacokinetic Study in Healthy Adult Volunteers to Evaluate the Bioavailability of ABBV-8736 Following Subcutaneous Administration Relative to Intravenous Administration

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Feb 11, 2026

Primary completion

Jun 19, 2026

Study completion Jun 19, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-8736Drug

    Intravenous Injection

  • ABBV-8736Drug

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to At Least 3 Months
  2. Maximum Observed Serum Concentration (Cmax) of ABBV-8736Time frame: Up to At Least 3 Months
  3. Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736Time frame: Up to At Least 3 Months
  4. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736Time frame: Up to At Least 3 Months
  5. AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736Time frame: Up to At Least 3 Months
  6. Terminal Phase Elimination Rate Constant (β) of ABBV-8736Time frame: Up to At Least 3 Months
  7. Terminal Elimination Half-Life (t1/2) of ABBV-8736Time frame: Up to At Least 3 Months
  8. Apparent Clearance of the Analyte in Serum (CL) of ABBV-8736Time frame: Up to At Least 3 Months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel ACT- Anaheim Clinical Trials /ID# 280481

    Anaheim, California

  • Acpru /Id# 280382

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.